<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00312338</url>
  </required_header>
  <id_info>
    <org_study_id>CMS-05-11</org_study_id>
    <nct_id>NCT00312338</nct_id>
  </id_info>
  <brief_title>Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora</brief_title>
  <official_title>Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tufts University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Alcon Research</source>
  <brief_summary>
    <textblock>
      Topical Treatment of Bacterial Conjunctivitis and its Effect on Microbial Flora
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Susceptability Changes in Streptococcus Pneumoniae Distal to the Site of Instillation</measure>
    <time_frame>Day 0 and Day 42</time_frame>
    <description>Susceptibility change refers to a change in vulnerability of a specified bacterial strain to antibiotic treatment. Susceptibility was assessed by broth microdilution methods recommended by the Clinical and Laboratory Standards Institute (CLSI).
0% = zero isolates were resistant to antibiotic 100% = all isolates were resistant to antibiotic</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Susceptability Changes in Staphylococcus Aureus Distal to the Site of Instillation</measure>
    <time_frame>Day 0, Day 42</time_frame>
    <description>Susceptibility change refers to a change in vulnerability of a specified bacterial strain to antibiotic treatment. Susceptibility was assessed by broth microdilution methods recommended by the Clinical and Laboratory Standards Institute (CLSI).
0% = zero isolates were resistant to antibiotic 100% = all isolates were resistant to antibiotic</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Susceptability Changes in Haemophilus Influenzae Distal to the Site of Instillation</measure>
    <time_frame>Day 0, Day 42</time_frame>
    <description>Susceptibility change refers to a change in vulnerability of a specified bacterial strain to antibiotic treatment. Susceptibility was assessed by broth microdilution methods recommended by the Clinical and Laboratory Standards Institute (CLSI).
0% = zero isolates were resistant to antibiotic 100% = all isolates were resistant to antibiotic</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">137</enrollment>
  <condition>Bacterial Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>Infected Patient treated with Vigamox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conjunctivitis-Infected Patient receiving Vigamox 0.5% in both eyes three times daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Subjects</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Healthy Subjects receiving no treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VIGAMOX</intervention_name>
    <description>1 drop of VIGAMOXÂ® ophthalmic solution 0.5% in both eyes TID for 7 days</description>
    <arm_group_label>Infected Patient treated with Vigamox</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients from 1 to 13 years of age that have diagnosis of bacterial conjunctivitis in
             either or both eyes (for &lt; 3 days duration) based on clinical observation; matched
             healthy controls

        Exclusion Criteria:

          -  Cannot have had bacterial conjunctivitis symptoms as reported by parent for &gt; 2 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>13 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven J. Lichtenstein, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Investigator / Contact</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Multiple Locations</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2006</study_first_submitted>
  <study_first_submitted_qc>April 4, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2006</study_first_posted>
  <results_first_submitted>July 15, 2009</results_first_submitted>
  <results_first_submitted_qc>January 13, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 2, 2010</results_first_posted>
  <last_update_submitted>October 31, 2012</last_update_submitted>
  <last_update_submitted_qc>October 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
    <mesh_term>Moxifloxacin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study recruitment started in June 2006 and ran until January 29 2008. The study sites included three sites (AZ, CA and IL)</recruitment_details>
      <pre_assignment_details>No specific pre-assignment activities.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Infected Patients</title>
          <description>Infected Patients</description>
        </group>
        <group group_id="P2">
          <title>Healthy Subjects</title>
          <description>Healthy Subjects</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subsequent infection</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Infected Patients</title>
          <description>Infected Patients</description>
        </group>
        <group group_id="B2">
          <title>Healthy Subjects</title>
          <description>Healthy Subjects</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="105"/>
            <count group_id="B2" value="57"/>
            <count group_id="B3" value="162"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Susceptability Changes in Streptococcus Pneumoniae Distal to the Site of Instillation</title>
        <description>Susceptibility change refers to a change in vulnerability of a specified bacterial strain to antibiotic treatment. Susceptibility was assessed by broth microdilution methods recommended by the Clinical and Laboratory Standards Institute (CLSI).
0% = zero isolates were resistant to antibiotic 100% = all isolates were resistant to antibiotic</description>
        <time_frame>Day 0 and Day 42</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Infected Patients</title>
            <description>Infected Patients</description>
          </group>
          <group group_id="O2">
            <title>Healthy Subjects</title>
            <description>Healthy Subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Susceptability Changes in Streptococcus Pneumoniae Distal to the Site of Instillation</title>
          <description>Susceptibility change refers to a change in vulnerability of a specified bacterial strain to antibiotic treatment. Susceptibility was assessed by broth microdilution methods recommended by the Clinical and Laboratory Standards Institute (CLSI).
0% = zero isolates were resistant to antibiotic 100% = all isolates were resistant to antibiotic</description>
          <units>Percent of resistant isolates</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Susceptability Changes in Staphylococcus Aureus Distal to the Site of Instillation</title>
        <description>Susceptibility change refers to a change in vulnerability of a specified bacterial strain to antibiotic treatment. Susceptibility was assessed by broth microdilution methods recommended by the Clinical and Laboratory Standards Institute (CLSI).
0% = zero isolates were resistant to antibiotic 100% = all isolates were resistant to antibiotic</description>
        <time_frame>Day 0, Day 42</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Infected Patients</title>
            <description>Infected Patients</description>
          </group>
          <group group_id="O2">
            <title>Healthy Subjects</title>
            <description>Healthy Subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Susceptability Changes in Staphylococcus Aureus Distal to the Site of Instillation</title>
          <description>Susceptibility change refers to a change in vulnerability of a specified bacterial strain to antibiotic treatment. Susceptibility was assessed by broth microdilution methods recommended by the Clinical and Laboratory Standards Institute (CLSI).
0% = zero isolates were resistant to antibiotic 100% = all isolates were resistant to antibiotic</description>
          <units>Percent of resistant isolates</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Susceptability Changes in Haemophilus Influenzae Distal to the Site of Instillation</title>
        <description>Susceptibility change refers to a change in vulnerability of a specified bacterial strain to antibiotic treatment. Susceptibility was assessed by broth microdilution methods recommended by the Clinical and Laboratory Standards Institute (CLSI).
0% = zero isolates were resistant to antibiotic 100% = all isolates were resistant to antibiotic</description>
        <time_frame>Day 0, Day 42</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Infected Patients</title>
            <description>Infected Patients</description>
          </group>
          <group group_id="O2">
            <title>Healthy Subjects</title>
            <description>Healthy Subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Susceptability Changes in Haemophilus Influenzae Distal to the Site of Instillation</title>
          <description>Susceptibility change refers to a change in vulnerability of a specified bacterial strain to antibiotic treatment. Susceptibility was assessed by broth microdilution methods recommended by the Clinical and Laboratory Standards Institute (CLSI).
0% = zero isolates were resistant to antibiotic 100% = all isolates were resistant to antibiotic</description>
          <units>Percent of resistant isolates</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 0 to Day 42</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Infected Patients</title>
          <description>Infected Patients</description>
        </group>
        <group group_id="E2">
          <title>Healthy Subjects</title>
          <description>Healthy Subjects</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limited source documents.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Alcon Clinical</name_or_title>
      <organization>Alcon Research, Ltd.</organization>
      <phone>888.451.3937; 817.568.6725</phone>
      <email>medinfo@alconlabs.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

